LianBio - ADR

LIAN | $4.92 0.41% 0.41% 410K

(0.0% 1d) (0.0% 1m) (136.2% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (40.69% volume)
Earnings Calendar:
Market Cap: $ 531,668,179

Sec Filling | Patents | 2021 employees

lianbio’s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in china and major asian markets through partnerships that provide access to the best science-driven therapeutic discoveries. lianbio collaborates with world-class partners across a diverse array of therapeutic and geographic areas to build out a pipeline based on disease relevance and the ability to impact patients with transformative mechanisms and precision-based therapeutics.

add to watch list Paper trade email alert is off

IonQ Inc

IONQ 4 | $7.37 1.24% 0.0% 4.1M

Professional, Scientific, and T...

(0.0% 1d) (-21.2% 1m) (15.9% 1y) (0.0% 2d) (-3.2% 3d) (-9.3% 7d) (-25.41% volume)
Earnings Calendar:
Market Cap: $ 1,534,651,555
https://ionq.com
Sec Filling | Patents | n/a employees

IonQ, Inc. is a leader in quantum computing, with a proven track record of innovation and deployment. IonQ’s next-generation quantum computer is the world’s most powerful trapped-ion quantum computer, and IonQ has defined what it believes is the best path forward to scale. IonQ is the only company with its quantum systems available through the cloud on Amazon Braket, Microsoft Azure, and Google Cloud, as well as through direct API access. IonQ was founded in 2015 by Christopher Monroe and Jungsang Kim based on 25 years of pioneering research.

computational

add to watch list Paper trade email alert is off

Recursion Pharmaceuticals Inc - Class A

RXRX | $7.41 -0.8% -0.81% 2.9M

Professional, Scientific, and T...

(0.0% 1d) (-30.5% 1m) (25.3% 1y) (0.0% 2d) (-1.3% 3d) (-11.2% 7d) (-8.84% volume)
Earnings Calendar: 2024-02-26
Market Cap: $ 1,683,132,601
https://www.recursionpharma.com
Sec Filling | Patents | n/a employees

Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Central to its mission is the Recursion Operating System, or Recursion OS, that combines an advanced infrastructure layer to generate what Recursion believes is one of the world's largest and fastest-growing proprietary biological and chemical datasets and the Recursion Map, a suite of custom software, algorithms, and machine learning tools that the company uses to explore foundational biology unconstrained by human bias and navigate to new biological insights which may accelerate its programs. biotechnology company scaling more like a technology company.

drug discovery machine learning

add to watch list Paper trade email alert is off

Sunshine Biopharma, Inc

SBFM | $3.315 -12.76% -14.63% 2.7M

Professional, Scientific, and T...

(0.0% 1d) (12263.6% 1m) (871.4% 1y) (0.0% 2d) (0.0% 3d) (8389.4% 7d) (-97.39% volume)
Earnings Calendar:
Market Cap: $ 329,686,247

Sec Filling | Patents | 3 employees

sunshine biopharma inc (sbfm) is a pharmaceuticals company based out of 469 jean-talon west, 3rd floor, montreal, québec, canada.

add to watch list Paper trade email alert is off

BIOXYTRAN, INC

BIXT | $0.123 490.75% 34K

Professional, Scientific, and T...

(0.0% 1d) (4.7% 1m) (-76.5% 1y) (0.0% 2d) (0.0% 3d) (-22.0% 7d) (328.31% volume)
Earnings Calendar:
Market Cap: $ 21,399,789
https://www.bioxytraninc.com/
Sec Filling | Patents | 3 employees

(US) bioxytran, inc., an early stage pharmaceutical company, focuses on the development, manufacture, and commercialization of various therapeutic drugs to address hypoxia in humans. the company's lead pharmaceutical drug candidate is bxt-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for the treatment of patients with ischemia of the brain resulting from a stroke or the blockage of the blood vessels to the brain. its products also include bxt-252, an injectable anti-necrosis drug to treat a wound that does not heal because limited amount of oxygen reaching the wound. the company was founded in 2017 and is headquartered in newton, massachusetts.

injection

add to watch list Paper trade email alert is off

Biomea Fusion Inc

BMEA | $11.18 -2.78% -2.86% 1.7M

Professional, Scientific, and T...

(0.0% 1d) (-22.0% 1m) (-56.5% 1y) (0.0% 2d) (0.0% 3d) (-7.9% 7d) (-13.61% volume)
Earnings Calendar: 2023-11-06
Market Cap: $ 401,243,045
https://www.biomeafusion.com
Sec Filling | Patents | 12 employees

Biomea Fusion, Inc. operates as a biopharmaceutical company. The Company focuseS on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Biomea Fusion serves customers in the United States.

genetic cancer msa

add to watch list Paper trade email alert is off

BioRestorative Therapies, Inc.

BRTX | $1.435 3.24% 3.14% 250K

Professional, Scientific, and T...

(0.0% 1d) (-6.4% 1m) (-64.9% 1y) (0.0% 2d) (0.0% 3d) (-2.2% 7d) (42767.95% volume)
Earnings Calendar:
Market Cap: $ 9,714,834
http://www.biorestorative.com/
Sec Filling | Patents | 5 employees

(US) biorestorative therapies, inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders: • disc/spine program (brtxdisc™): our lead cell therapy candidate, brtx-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. we intend that the product will be used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. the brtx-100 production process involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. in an outpatient procedure, brtx-100 is to be injected by a physician into the patient’s damaged disc. the treatment is intended for patients whose pain has not been alleviated by non-invas

injection t-cell

add to watch list Paper trade email alert is off